Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 9/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871386 | 0.87 | MAPT (0.41) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL4879634 | 0.83 | KDM4E (0.46) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL4876609 | 0.81 | RAB9A (0.45) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL4875441 | 0.80 | RAB9A (0.48) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL644797 | 0.78 | FFAR1 (0.49) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL20838307 | 0.78 | MEN1 (0.51) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL4879486 | 0.75 | GPBAR1 (0.51) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL4873239 | 0.75 | KDM4E (0.45) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL28963021 | 0.75 | FFAR1 (0.41) | ALDH1A1KDM4ENPC1RAB9AFFAR1 | |
| SCHEMBL18311238 | 0.74 | KAT6A (0.52) | ALDH1A1KDM4ENPC1RAB9AFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | NOVARTIS AG (CH) | 2008-06-05 | — | — | US | disclosed |
| EP-1851208-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006074950-A1 | MACROCYCLIC COMPOUNDS USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132477-A1 | Macrocyclic Compounds Useful as Bace Inhibitors | BACE1, BACE2, APP | ALDH1A1 2631/4885KDM4E 3337/4885NPC1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.